<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6471">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01014871</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.29081</org_study_id>
    <nct_id>NCT01014871</nct_id>
  </id_info>
  <brief_title>Comparison of Two Botulinum Toxins Type A on Forehead Wrinkles</brief_title>
  <official_title>Intra-individual Comparison of the Efficacy of Two Botulinum Toxins Type A on Moderate to Severe Forehead Wrinkles After One Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-centre, controlled, randomized, evaluator-blinded, bilateral (split-face) comparison
      study in subjects with moderate to severe forehead wrinkles.

      One botulinum toxin type A will be injected in one side of the forehead and the other one
      will be injected in the other side of the forehead at baseline. Allocation of each BoNT-A to
      each side of the forehead will be randomized.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are two formulations of BoNT-A available: Botox®/Vistabel®, Allergan and
      Dysport®/Azzalure®, Ipsen - Galderma. These formulations behave distinctly in different ways
      electrophysiologically and clinically and results obtained with one formulation cannot be
      extrapolated to the other. There are only few clinical research directly comparing the two
      formulations in the treatment of forehead lines.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Severity of the Forehead Wrinkles by the Evaluator at Maximum Contraction and at Rest Using the Forehead Wrinkles Severity Scale (0 to 3) at Each Study Visit and for Each Side of the Forehead</measure>
    <time_frame>5 months : Baseline, Days 1, 2, 3, 7, 10, 14, 30, Months 4 and 5</time_frame>
    <safety_issue>No</safety_issue>
    <description>Bilateral comparison of forehead wrinkle severity score at rest and at maximum contraction measured by Forehead Wrinkles Severity Scale (0 to 3) at each study visit (Baseline, Days 1, 2, 3, 7, 10, 14, 30, Months 4 and 5)and for each side.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Wrinkles</condition>
  <arm_group>
    <arm_group_label>intra-individual comparison</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A - Azzalure</intervention_name>
    <description>One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.</description>
    <arm_group_label>intra-individual comparison</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A - Vistabel</intervention_name>
    <description>One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.</description>
    <arm_group_label>intra-individual comparison</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female Subjects of any race, from 18 to 65 years old

          2. Moderate to severe horizontal forehead wrinkles at maximum contraction (2-3 on the
             Forehead Wrinkles Severity Scale) on both sides of the forehead

          3. Negative urine pregnancy test at the Baseline visit for Subjects of childbearing
             potential

        Exclusion Criteria:

          1. Subjects with a washout period for procedure(s)/treatment(s) on the forehead less
             than:

               -  Retinoid, microdermabrasion, or prescription level glycolic acid treatments 2
                  weeks

               -  Non-ablative light treatments (e.g. Intense Pulsed Light, light-emitting diodes)
                  1 month

               -  Ablative skin resurfacing

               -  Non-ablative dermal treatment for skin tightening (e.g. radio-frequency
                  treatments) 6 months

               -  Treatment with a BoNT-A 12 months

               -  Soft tissue augmentation (e.g. biodegradable products as collagen or hyaluronic
                  acid preparations) 24 months

          2. Subjects who undergone a surgical facelift;

          3. Permanent or semi-permanent dermal fillers in the forehead area;

          4. Known allergy or hypersensitivity to any botulinum toxin or any component of BoNT-A
             (1) and/or BoNT-A (2) (see package inserts);

          5. Concurrent use of treatments that affect neuromuscular transmission, such as
             curare-like depolarizing agents, lincosamides, polymyxins, anticholinesterases
             affecting the striated muscle and aminoglycoside antibiotics;

          6. Pregnant women, nursing mothers, or women who are planning pregnancy during the
             study;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pr Rzany, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>La Charité Hospital, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>La Charité Hospital</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <lastchanged_date>April 17, 2012</lastchanged_date>
  <firstreceived_date>November 16, 2009</firstreceived_date>
  <firstreceived_results_date>August 12, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Forehead Wrinkles Toxin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment process: patients from private practice - Recruitment period: First Patient In = 13 July 2009 Last Patient In = 09 November 2009 - Type of location: hospital</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Vistabel/Azzalure</title>
          <description>at Baseline:
1 injection of 20 units of Azzalure (2 points of 10 units) in 1 side of the forehead
1 injection of 8 Speywood units of Vistabel (2 points of 4 Speywood units) in the other side of the forehead</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vistabel/Azzalure</title>
          <description>at Baseline:
1 injection of 20 units of Azzalure (2 points of 10 units) in 1 side of the forehead
1 injection of 8 Speywood units of Vistabel (2 points of 4 Speywood units) in the other side of the forehead</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="46.4" spread="8.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Germany</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Severity of the Forehead Wrinkles by the Evaluator at Maximum Contraction and at Rest Using the Forehead Wrinkles Severity Scale (0 to 3) at Each Study Visit and for Each Side of the Forehead</title>
        <description>Bilateral comparison of forehead wrinkle severity score at rest and at maximum contraction measured by Forehead Wrinkles Severity Scale (0 to 3) at each study visit (Baseline, Days 1, 2, 3, 7, 10, 14, 30, Months 4 and 5)and for each side.</description>
        <time_frame>5 months : Baseline, Days 1, 2, 3, 7, 10, 14, 30, Months 4 and 5</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intention To Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Azzalure</title>
            <description>at Baseline:
- 1 injection of 20 units of Azzalure (2 points of 10 units) in 1 side of the forehead</description>
          </group>
          <group group_id="O2">
            <title>Vistabel</title>
            <description>at Baseline:
- 1 injection of 8 Speywood units of Vistabel (2 points of 4 Speywood units) in the other side of the forehead</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Severity of the Forehead Wrinkles by the Evaluator at Maximum Contraction and at Rest Using the Forehead Wrinkles Severity Scale (0 to 3) at Each Study Visit and for Each Side of the Forehead</title>
            <description>Bilateral comparison of forehead wrinkle severity score at rest and at maximum contraction measured by Forehead Wrinkles Severity Scale (0 to 3) at each study visit (Baseline, Days 1, 2, 3, 7, 10, 14, 30, Months 4 and 5)and for each side.</description>
            <units>Scores on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline at rest</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4" spread="0.5"/>
                  <measurement group_id="O2" value="1.4" spread="0.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 1 at rest</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.3" spread="0.5"/>
                  <measurement group_id="O2" value="1.3" spread="0.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 2 at rest</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" spread="0.6"/>
                  <measurement group_id="O2" value="1.0" spread="0.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 3 at rest</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.9" spread="0.6"/>
                  <measurement group_id="O2" value="0.8" spread="0.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 7 at rest</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.7" spread="0.7"/>
                  <measurement group_id="O2" value="0.7" spread="0.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 10 at rest</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.5" spread="0.6"/>
                  <measurement group_id="O2" value="0.5" spread="0.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 14 at rest</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.6" spread="0.6"/>
                  <measurement group_id="O2" value="0.5" spread="0.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 30 at rest</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.6" spread="0.6"/>
                  <measurement group_id="O2" value="0.6" spread="0.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 4 at rest</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" spread="0.5"/>
                  <measurement group_id="O2" value="1.0" spread="0.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 5 at rest</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.2" spread="0.6"/>
                  <measurement group_id="O2" value="1.3" spread="0.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Baseline at maximum contraction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.1" spread="0.3"/>
                  <measurement group_id="O2" value="2.1" spread="0.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 1 at maximum contraction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.8" spread="0.6"/>
                  <measurement group_id="O2" value="1.8" spread="0.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 2 at maximum contraction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.6" spread="0.6"/>
                  <measurement group_id="O2" value="1.5" spread="0.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 3 at maximum contraction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.2" spread="0.7"/>
                  <measurement group_id="O2" value="1.1" spread="0.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 7 at maximum contraction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.7" spread="0.7"/>
                  <measurement group_id="O2" value="0.7" spread="0.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 10 at maximum contraction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.6" spread="0.7"/>
                  <measurement group_id="O2" value="0.6" spread="0.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 14 at maximum contraction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.5" spread="0.6"/>
                  <measurement group_id="O2" value="0.4" spread="0.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Day 30 at maximum contraction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.5" spread="0.6"/>
                  <measurement group_id="O2" value="0.5" spread="0.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 4 at maximum contraction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.5" spread="0.5"/>
                  <measurement group_id="O2" value="1.4" spread="0.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 5 at maximum contraction</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.8" spread="0.6"/>
                  <measurement group_id="O2" value="1.9" spread="0.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 months</time_frame>
      <desc>All medical clinical events occurred after subject’s consent signature and during the study, whether observed by the Evaluator/Injector or reported by the Subject and whether or not thought to be treatment-related were considered adverse events and collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Azzalure</title>
          <description>intra-individual comparison</description>
        </group>
        <group group_id="E2">
          <title>Vistabel</title>
          <description>intra-individual comparison</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>EYELID PTOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DENTAL DISCOMFORT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>INJECTION SITE PARAESTHESIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>SENSATION OF HEAVINESS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>FACIAL PARESIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PHARYNGOLARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>EYELID OEDEMA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Disclosure agreement in full force and effect for a period of 10 years.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Florence Paliargues / CPM</name_or_title>
      <organization>Galderma</organization>
      <phone>+33492952957</phone>
      <email>florence.paliargues@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
